Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Benchmark Holdings Plc Share Issue/Capital Change 2020

Mar 20, 2020

6035_rns_2020-03-20_b11f335e-139c-46e0-a4eb-d3d93b329590.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8426G

Benchmark Holdings PLC

20 March 2020

BLOCK LISTING SIX MONTHLY RETURN

Date: 20 March 2020

Name of applicant: Benchmark Holdings plc
Name of scheme: The Enterprise Management Incentive (EMI) scheme and CSOP scheme
Period of return: From: 21 September 2019 To: 20 March 2020
Balance of unallotted securities under scheme(s) from previous return: EMI scheme - 295,000

CSOP scheme - 2,088,480

Total - 2,383,480
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): EMI scheme - 0

CSOP scheme - 5,200,000 (subject to admission to AIM, expected to occur on 23 March 2020)

Total - 5,200,000 (subject to admission to AIM, expected to occur on 23 March 2020)
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): EMI scheme - 10,000

CSOP scheme - 1,353,964

Total - 1,363,964
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: EMI scheme - 285,000

CSOP scheme - 5,934,516 (of which 5,200,000 remain subject to admission to AIM, expected to occur on 23 March 2020)

Total - 6,219,516 (of which 5,200,000 remain subject to admission to AIM, expected to occur on 23 March 2020)
Name of contact: Jennifer Haddouk, Company Secretary
Telephone number of contact: 44 (0) 330 313 0522

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BLRUKRSRRVUOAAR